Table 4. Impact of LD on outcome in... | American Society of Hematology

Table 4.

Impact of LD on outcome in cytogenetically defined subgroups

	Analysis after induction therapy†			Analysis after consolidation therapy
	RFS			RFS			OS
	P	RR (95% Cl)	P	RR (95% Cl)	P	RR (95% Cl)
Favorable karyotype	n.a.*	—	n.s.	—	n.s.	—
Intermediate karyotype	.004	0.265 (0.107-0.653)	.006	0.460 (0.263-0.805)	.040	0.388 (0.157-0.959)
Unfavorable karyotype	.030	0.330 (0.121-0.897)	.033	0.253 (0.072-0.892)	n.s.	—

	Analysis after induction therapy†			Analysis after consolidation therapy
	RFS			RFS			OS
	P	RR (95% Cl)	P	RR (95% Cl)	P	RR (95% Cl)
Favorable karyotype	n.a.*	—	n.s.	—	n.s.	—
Intermediate karyotype	.004	0.265 (0.107-0.653)	.006	0.460 (0.263-0.805)	.040	0.388 (0.157-0.959)
Unfavorable karyotype	.030	0.330 (0.121-0.897)	.033	0.253 (0.072-0.892)	n.s.	—

Abbreviations are explained in a footnote to Table 2.

No events occurred in patients with a favorable karyotype.

†

Since there was no overall correlation between LD after induction therapy and OS, the respective correlations within cytogenetically defined subgroups were not analyzed.

View Large

This Feature Is Available To Subscribers Only